Scarica l'app Stockscreener
2.455
2.51%
0.065
Dopo l'orario di chiusura:
2.47
0.015
+0.61%
Precedente Chiudi:
$2.39
Aprire:
$2.42
Volume 24 ore:
253.59K
Relative Volume:
1.58
Capitalizzazione di mercato:
$13.13M
Reddito:
-
Utile/perdita netta:
$-23.92M
Rapporto P/E:
-0.0975
EPS:
-25.1834
Flusso di cassa netto:
$-22.74M
1 W Prestazione:
+4.26%
1M Prestazione:
-3.54%
6M Prestazione:
-65.00%
1 anno Prestazione:
-89.70%
Intervallo 1D:
$2.35
$2.49
Intervallo di 1 settimana:
$2.28
$2.49
Portata 52W:
$1.79
$24.00
Moleculin Biotech Inc Stock (MBRX) Company Profile
Nome
Moleculin Biotech Inc
Settore
Industria
Telefono
713-300-5160
Indirizzo
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
2.46 | 12.75M | 0 | -23.92M | -22.74M | -25.18 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-09 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-12 | Downgrade | Maxim Group | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
Moleculin Biotech Inc Borsa (MBRX) Ultime notizie
Moleculin Biotech, Inc. Files SEC Form 8-K and Releases May 2026 Investor Presentation - Minichart
Moleculin Biotech (NASDAQ: MBRX) posts new May 2026 investor presentation - Stock Titan
Moleculin Biotech Shares Slide After Announcing 1-for-25 Reverse Split - MSN
Why Did MBRX Stock Plummet Over 25% Today? - MSN
Annamycin cardiac safety data at ASCO 2026 for Moleculin (NASDAQ: MBRX) - Stock Titan
Moleculin presents cardiac safety data for Annamycin at ASCO By Investing.com - Investing.com South Africa
Moleculin's Annamycin shows no heart toxicity in trials, advancing AML cancer treatment. - Pluang
Moleculin presents cardiac safety data for Annamycin at ASCO - Investing.com
Pooled trials of cancer drug Annamycin find no cardiotoxicity signal - Stock Titan
Nano-cap Moleculin Biotech approaches key leukemia trial data unblinding - MSN
MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Moleculin Biotech stock (US60855L2034): Maxim Group keeps Buy rating - AD HOC NEWS
Moleculin Biotech 1Q Loss/Shr $3.54 >MBRX - Moomoo
Why did MBRX stock climb 14% today? - MSN
Moleculin Biotech: Runway to Support Planned Operations Into 3Q 2026 >MBRX - Moomoo
What Does GF Score 27/100 Say About Moleculin Biotech (MBRX) Aft - GuruFocus
Moleculin Biotech, Inc. (NASDAQ: MBRX) Reports Q1 2026 Financial Results and Clinical Trial Updates - Minichart
H.C. Wainwright Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Moleculin Biotech Q1 net loss widens as R&D costs rise - TradingView
Moleculin Biotech Reports Promising Early Results in MIRACLE Trial for AML Treatment with 40% Composite Complete Remission Rate - Quiver Quantitative
MBRX: Pivotal AML trial hits key enrollment, 40% remission rate; Q1 net loss $12.8M, cash runway into Q3 - TradingView
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Moleculin (NASDAQ: MBRX) Q1 2026 loss deepens while MIRACLE AML trial progresses - Stock Titan
Leukemia trial shows 40% remissions; first MIRACLE data unblinding due June 2026 - Stock Titan
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial - GlobeNewswire
Moleculin Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MBRX: Annamycin advanced in pivotal AML trial; net loss widened, and more funding is needed for operations - TradingView
Moleculin Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Moleculin Biotech (MBRX) widens Q1 loss and flags funding gap for MIRACLE trial - Stock Titan
Moleculin reports preliminary data from AML trial ahead of unblinding - Investing.com UK
Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding - Yahoo Finance
Moleculin Biotech (MBRX) Approaches Key Data Release in AML Tria - GuruFocus
Moleculin Biotech, Inc. Files Form 8-K for May 13, 2026 – Company Details, Stock Info, and Regulatory Disclosures - Minichart
Moleculin Biotech Incto unblind Miracle trial data before June 30, 2026SEC filing - marketscreener.com
Moleculin Nears First Unblinding in Pivotal MIRACLE Trial - TipRanks
Moleculin reports preliminary data from AML trial ahead of unblinding By Investing.com - Investing.com South Africa
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks - The Manila Times
Moleculin Approaching First MIRACLE Trial Unblinding; Preliminary CR ~30% vs 17–18% SOC - TradingView
Moleculin (NASDAQ: MBRX) posts higher blinded AML remission rates vs cytarabine - Stock Titan
Leukemia study nears June data reveal after early 30% remission rate - Stock Titan
Moleculin Biotech (MBRX) Highlights Annamycin's Cardiac Safety P - GuruFocus
Number of shareholders of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView
Moleculin Biotech, Inc. Files 8-K Report with SEC – Company and Stock Information as of May 12, 2026 - Minichart
Moleculin highlights favorable cardiac safety data for Annamycin - TipRanks
Moleculin reports cardiac safety data for Annamycin in AML study By Investing.com - Investing.com South Africa
Moleculin reports cardiac safety data for Annamycin in AML study - Investing.com
Moleculin Biotech, Inc. Publishes Positive Cardiac Safety Data for Annamycin in Relapsed/Refractory AML at EHA 2026 Congress - Quiver Quantitative
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits - The Manila Times
Independent Cleveland Clinic review finds no significant cardiotoxicity with Moleculin's Annamycin - TradingView
Cardiac data support Moleculin (NASDAQ: MBRX) Annamycin use in R/R AML - Stock Titan
Moleculin Biotech Inc Azioni (MBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moleculin Biotech Inc Azioni (MBRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
1.49%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):